SCHEMBL1857359

SCHEMBL1857359

CC(C)(CCCI)[N+](=O)[O-]

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22341413 0.85 ALDH1A1 (0.43) ALDH1A1L3MBTL1
SCHEMBL17030340 0.78 ALDH1A1 (0.44) ALDH1A1L3MBTL1
SCHEMBL14737887 0.76 ALDH1A1 (0.42) ALDH1A1L3MBTL1
SCHEMBL18918047 0.76 ALDH1A1 (0.36) ALDH1A1L3MBTL1
SCHEMBL1853215 0.76 ALDH1A1 (0.38) ALDH1A1L3MBTL1
SCHEMBL6185698 0.76 ALDH1A1 (0.48) ALDH1A1L3MBTL1
SCHEMBL27848826 0.76 ALDH1A1 (0.44) ALDH1A1
SCHEMBL12852874 0.73 MEN1 (0.36) ALDH1A1L3MBTL1
SCHEMBL3246663 0.73 ALDH1A1 (0.36) ALDH1A1L3MBTL1
SCHEMBL12852872 0.73 ALDH1A1 (0.33) ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197420-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2025-06-19 US disclosed
EP-2341886-B1 ANTIMICROBIAL N-CHLORINATED COMPOSITIONS NOVABAY PHARMACEUTICALS INC (US) 2015-08-26 EP disclosed
US-8278482-B2 Antimicrobial N-chlorinated compositions NOVABAY PHARMACEUTICALS, INC. (US) 2012-10-02 US disclosed
US-8278482-B2 Antimicrobial N-chlorinated compositions NOVABAY PHARMACEUTICALS, INC. (US) 2012-10-02 US disclosed
US-8278482-B2 Antimicrobial N-chlorinated compositions NOVABAY PHARMACEUTICALS, INC. (US) 2012-10-02 US disclosed
EP-2341886-A1 ANTIMICROBIAL N-CHLORINATED COMPOSITIONS NovaBay Pharmaceuticals, Inc. (US) 2011-07-13 EP disclosed
US-7939658-B2 Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-10 US disclosed
US-20100297028-A1 MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-25 US disclosed
US-20100158818-A1 ANTIMICROBIAL N-CHLORINATED COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100158818-A1 ANTIMICROBIAL N-CHLORINATED COMPOSITIONS NOVABAY PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20070203125-A1 Medicament Combinations for the Treatment of Respiratory Diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-30 US disclosed
US-7148371-B2 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2006-12-12 US disclosed
US-20060063817-A1 New betamimetics for the treatment of respiratory complaints BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-03-23 US disclosed
US-7012152-B2 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2006-03-14 US disclosed
US-20060004103-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2006-01-05 US disclosed
US-20040054216-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2004-03-18 US disclosed
US-6664412-B2 Protecting amino group or amino group and carboxyl group of optically active 2-amino-6-methyl-6-nitroheptanoic acid with protecting group, reducing nitro group to synthesize 6,6-dimethyllysine and reacting this with acetic acid AJINOMOTO CO., INC. (JP) 2003-12-16 US disclosed
US-20030105351-A1 Method for producing lysine derivative AJINOMOTO CO. INC (JP) 2003-06-05 US disclosed
US-20020042537-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2002-04-11 US disclosed
EP-1179599-A2 Method for producing lysine derivative Ajinomoto Co., Inc. (JP) 2002-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063817-A1 New betamimetics for the treatment of respiratory complaints CHRM1, ADRB1, ADRA1B ALDH1A1 1726/4885L3MBTL1 1683/4885
US-20030105351-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A ALDH1A1 553/4885L3MBTL1 1334/4885
US-20040054216-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A ALDH1A1 553/4885L3MBTL1 1334/4885
US-20250197420-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCB1, PKD1 ALDH1A1 3545/4885L3MBTL1 4499/4885
US-20020042537-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A ALDH1A1 553/4885L3MBTL1 1334/4885
US-20100158818-A1 ANTIMICROBIAL N-CHLORINATED COMPOSITIONS NRDC, NHERF1, MPO ALDH1A1 3343/4885L3MBTL1 3847/4885
US-20070203125-A1 Medicament Combinations for the Treatment of Respiratory Diseases CHRM1, CHRM2, MTNR1B ALDH1A1 993/4885L3MBTL1 2693/4885
US-20100297028-A1 MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES CHRM1, CHRM2, MTNR1B ALDH1A1 993/4885L3MBTL1 2693/4885
US-20060004103-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A ALDH1A1 553/4885L3MBTL1 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.